The Role of Behavioral Medicine in Reducing Opioid Use is organized by Haymarket Media Group.
Released: October 31, 2023
Expires: October 31, 2024
Program Description:
This activity focuses on utilizing behavioral medicine to reduce opioid use and covers all aspects of the core content outlined in the revised FDA Blueprint, with an emphasis on behavioral health and how the application of behavioral methods can help control pain. The content is broken down into four modules: The Basics of Pain Management, Creating the Pain Treatment Plan, Managing Patients with Pain on Opioid Analgesics, and Addiction Medicine Primer. This is a FDA REMS-compliant accredited CE activity.
Educational Objective
Upon completion of the educational activity, participants should be able to:
• Describe the fundamental concepts of pain management
• Assess patients with pain, including mental health (ie, depression, anxiety, etc), and identify potential risk factors for opioid use disorder and who could benefit from behavioral health services
• Utilize the range of therapeutic options for managing pain, including non-pharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies with a focus on the inclusion of behavioral therapy
• Manage patients on opioid analgesics safely and effectively in acute and chronic pain settings, including initiating therapy, titrating, and discontinuing use of opioid analgesics, with a focus on discontinuation of opioids and the use of behavioral medicine
• Counsel patients and caregivers on the safe use of opioid analgesics along with behavioral medicine approaches
• Counsel patients and caregivers about the use of naloxone for opioid overdose
• Refer patients to a pain specialist, as appropriate
• Utilize the fundamental elements of addiction medicine (ie, diagnosis, prevention, evaluation, treatment, and recovery of patients with opioid use disorder)
• Identify and manage the care of patients with opioid use disorder, including behavioral medicine approaches
• Identify current information about safe opioid practices and current federal and state regulations, national guidelines, and professional organization and medical specialty guidelines on treating pain and prescribing opioids
• Detail the use of naloxone and the importance of its availability for use by patients and caregivers in the community and home
Additional details will be posted as soon as information is available.
Accredited Provider
This activity is provided by Cleveland Clinic Center for Continuing Education.
Joint Accreditation Statement
In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA PRA Category 1 CreditsTM
Designation Statement
Cleveland Clinic Center for Continuing Education designates this enduring material for a maximum of 2.00 AMA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
AAPA Category 1 CME Credits
Designation Statement
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.00 AAPA Category 1 CME credits. Approval is valid until 10/31/2024. PAs should only claim credit commensurate with the extent of their participation.
ANCC Contact Hours
Designation Statement
Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 2.00 ANCC contact hours.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved